Take Advantage of Earnings Volatility
Pfizer (PFE) ($24.58 vs. $25.43 on Oct. 29): When the stock market reopened Oct. 31 this stock traded up to my quarterly risky level at $25.74, where profits should have been taken. The stock is now below its 50-day SMA at $24.79. The weekly chart profile is negative with the five-week MMA at $24.78. My semiannual value level is $20.51 with the quarterly pivot at $25.74.
Barrick Gold (ABX) ($35.08 vs. $39.18 on Oct. 29): Tested its 200-day SMA at $40.69 Wednesday for an opportunity to sell strength. I do not show a value level but my semiannual pivot is $37.60.
Teva Pharmaceuticals (TEVA) ($41.14 vs. $40.39 on Oct. 29): The stock is trading between its 50-day SMA at $40.40 and its 200-day SMA at $41.80.
Exxon Mobil (XOM) ($90.63 vs. $90.62 on Oct. 29): Weakness on Monday held my monthly pivot at $89.78 with the close just below the 50-day SMA at $90.77. The weekly chart shifts to negative on a close this week below the five-week MMA at $90.62. This week's risky level is $92.87.
Newmont Mining (NEM) ($48.39 vs. $53.07 on Oct. 29): My annual pivot and semiannual risky level at $53.89 and $54.88 last Wednesday where investors and traders were advised to sell strength. The stock ended last week below my quarterly pivot at $49.36. My new monthly value level is $41.67. Starbucks (SBUX) ($51.01 vs. $45.87 on Oct. 29): Matched revenue estimates and gave an optimistic outlook. The stock popped above my semiannual pivot at $49.81 on Friday to a test of its 200-day SMA at $51.37. My annual value level is $44.25 with a monthly risky level at $53.41. Chevron (CVX) ($109.19 vs. $111.18 on Oct. 29): Traded down from $111.94 last Wednesday to a test of its 200-day SMA at $107.57 on Friday. My monthly value level is $107.67 with a weekly risky level at $113.22. At the time of publication the author held no positions in any of the stocks mentioned. Follow @Suttmeier This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV